Dyadic International rapidly developed stable C1 cell lines and produced purified Bundibugyo Ebola virus antigens within approximately 15 days, delivering them for preclinical evaluation of a potential non-mRNA vaccine. This rapid production is crucial amid the active Bundibugyo ebolavirus outbreak, which currently lacks approved vaccines or treatments. Dyadic's C1 platform offers a scalable, cost-effective alternative to traditional methods, potentially accelerating vaccine and antibody development during health emergencies. The company aims to expand its platform's adoption and commercial opportunities in biologics manufacturing, supported by collaborations with global health organizations and funding from the Gates Foundation.
Milestone Pharmaceuticals announced the grant of 33,000 stock options to a newly hired employee as an inducement under Nasdaq Listing Rule 5635(c)(4). The options, priced at $0.72 each, will vest over four years with a one-year cliff and monthly inst...
Zoetis is expected to outperform low market expectations for Q3 and Q4, with consensus and management forecasting declines in revenue and earnings per share. However, the company's diverse growth drivers, including expanding parasite prevention produ...
Oil prices slipped as traders remained cautious about the uncertain outcome of Iran nuclear talks, which continue to impact supply expectations. US crude stocks unexpectedly dropped by 5.27 million barrels, signaling tighter supply, but the official ...
Diana Shipping (DSX) is rated a buy as it trades significantly below its net asset value, largely supported by its 14.9% stake in Genco (GNK), which covers nearly 60% of DSX's market cap. The company's 36-ship fleet is valued at about $1 per share de...
Zcash (ZEC) saw a 3.31% price increase in the hour ending at 12:25 a.m. ET on Nov. 4, reaching $1,234 on Binance's spot market. Over the past 24 hours, ZEC's price rose 8.48%, reflecting strong positive momentum. Liquidations during the hour were mos...
